Abbott developing test for monkeypox
Reuters
Published May 26, 2022 01:48PM ET
By Leroy Leo
(Reuters) -Abbott Laboratories said on Thursday it is actively developing a test for monkeypox, as the disease spreads in various countries.
The company will provide the test kits to partners of its Pandemic Defense Coalition, a network of scientific and public health partnerships aimed at identifying future pandemic threats, an Abbott spokesperson told Reuters.
"As the situation evolves, we will take steps to address additional testing needs," the spokesperson said.
Abbott's announcement comes on a day when the Centers for Diseases Control and Prevention (CDC) confirmed it has identified nine monkeypox cases in seven U.S. states.
Globally, more than 200 confirmed or suspected infections have been recorded in around 20 countries where monkeypox is not endemic. Most of these cases have been found in Europe.
Abbott is the second company to announce its development of monkeypox tests following Roche's announcement on Wednesday.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.